Loading company…
Nanjing-based Iaso Biotherapeutics develops CAR-T and biologic cancer therapies, including CT103A for relapsed multiple myeloma.
Based in Nanjing, China, and founded in 2017 by Brian K. Hall, Nanjing Iaso Biotherapeutics Co., Ltd. develops cell therapies for cancer. CEO Dr. Wen Wang leads the company. Its clinical pipeline includes autologous and allogeneic CAR-T and biologics, including CT103A, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma, and a CD19/CD22 dual-targeted CAR-T therapy for B-cell lymphoma and leukemia. In September 2021 it raised USD 108 million in Series C funding led by CDH Baifu Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Nanjing Iaso Biotherapeutics Co., Ltd.? This is my company